Cargando…

Long-term outcomes following first short-term clinically important deterioration in COPD

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by varying trajectories of decline. Information regarding the prognostic value of preventing short-term clinically important deterioration (CID) in lung function, health status, or first moderate/severe exacerbation as a compo...

Descripción completa

Detalles Bibliográficos
Autores principales: Naya, Ian P., Tombs, Lee, Muellerova, Hana, Compton, Christopher, Jones, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245880/
https://www.ncbi.nlm.nih.gov/pubmed/30453972
http://dx.doi.org/10.1186/s12931-018-0928-3
_version_ 1783372334683389952
author Naya, Ian P.
Tombs, Lee
Muellerova, Hana
Compton, Christopher
Jones, Paul W.
author_facet Naya, Ian P.
Tombs, Lee
Muellerova, Hana
Compton, Christopher
Jones, Paul W.
author_sort Naya, Ian P.
collection PubMed
description BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by varying trajectories of decline. Information regarding the prognostic value of preventing short-term clinically important deterioration (CID) in lung function, health status, or first moderate/severe exacerbation as a composite endpoint of worsening is needed. We evaluated post hoc the link between early CID and long-term adverse outcomes. METHODS: CID was defined as ≥100 mL decrease in forced expiratory volume in 1 s (FEV(1)), ≥4-unit increase in St George’s Respiratory Questionnaire (SGRQ) score from baseline, and/or a moderate/severe exacerbation during enrollment in two 3-year studies. Presence of CID was assessed at 6 months for the principal analysis (TORCH) and 12 months for the confirmatory analysis (ECLIPSE). Association between presence (+) or absence (-) of CID and long-term deterioration in FEV(1), SGRQ, future risk of exacerbations, and all-cause mortality was assessed. RESULTS: In total, 2870 (54%; TORCH) and 1442 (73%; ECLIPSE) patients were CID+. At 36 months, in TORCH, CID+ patients (vs CID-) had sustained clinically significant worsening of FEV(1) (- 117 mL; 95% confidence interval [CI]: - 134, - 100 mL; P < 0.001) and SGRQ score (+ 6.42 units; 95% CI: 5.40, 7.45; P < 0.001), and had higher risk of exacerbations (hazard ratio [HR]: 1.61 [95% CI: 1.50, 1.72]; P < 0.001) and all-cause mortality (HR: 1.41 [95% CI: 1.15, 1.72]; P < 0.001). Similar risks post-CID were observed in ECLIPSE. CONCLUSIONS: A CID within 6–12 months of follow-up was consistently associated with increased long-term risk of exacerbations and all-cause mortality, and predicted sustained meaningful loss in FEV(1) and health status amongst survivors. TRIAL REGISTRATION: NCT00268216; NCT00292552. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12931-018-0928-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6245880
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62458802018-11-26 Long-term outcomes following first short-term clinically important deterioration in COPD Naya, Ian P. Tombs, Lee Muellerova, Hana Compton, Christopher Jones, Paul W. Respir Res Research BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterized by varying trajectories of decline. Information regarding the prognostic value of preventing short-term clinically important deterioration (CID) in lung function, health status, or first moderate/severe exacerbation as a composite endpoint of worsening is needed. We evaluated post hoc the link between early CID and long-term adverse outcomes. METHODS: CID was defined as ≥100 mL decrease in forced expiratory volume in 1 s (FEV(1)), ≥4-unit increase in St George’s Respiratory Questionnaire (SGRQ) score from baseline, and/or a moderate/severe exacerbation during enrollment in two 3-year studies. Presence of CID was assessed at 6 months for the principal analysis (TORCH) and 12 months for the confirmatory analysis (ECLIPSE). Association between presence (+) or absence (-) of CID and long-term deterioration in FEV(1), SGRQ, future risk of exacerbations, and all-cause mortality was assessed. RESULTS: In total, 2870 (54%; TORCH) and 1442 (73%; ECLIPSE) patients were CID+. At 36 months, in TORCH, CID+ patients (vs CID-) had sustained clinically significant worsening of FEV(1) (- 117 mL; 95% confidence interval [CI]: - 134, - 100 mL; P < 0.001) and SGRQ score (+ 6.42 units; 95% CI: 5.40, 7.45; P < 0.001), and had higher risk of exacerbations (hazard ratio [HR]: 1.61 [95% CI: 1.50, 1.72]; P < 0.001) and all-cause mortality (HR: 1.41 [95% CI: 1.15, 1.72]; P < 0.001). Similar risks post-CID were observed in ECLIPSE. CONCLUSIONS: A CID within 6–12 months of follow-up was consistently associated with increased long-term risk of exacerbations and all-cause mortality, and predicted sustained meaningful loss in FEV(1) and health status amongst survivors. TRIAL REGISTRATION: NCT00268216; NCT00292552. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12931-018-0928-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-20 2018 /pmc/articles/PMC6245880/ /pubmed/30453972 http://dx.doi.org/10.1186/s12931-018-0928-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Naya, Ian P.
Tombs, Lee
Muellerova, Hana
Compton, Christopher
Jones, Paul W.
Long-term outcomes following first short-term clinically important deterioration in COPD
title Long-term outcomes following first short-term clinically important deterioration in COPD
title_full Long-term outcomes following first short-term clinically important deterioration in COPD
title_fullStr Long-term outcomes following first short-term clinically important deterioration in COPD
title_full_unstemmed Long-term outcomes following first short-term clinically important deterioration in COPD
title_short Long-term outcomes following first short-term clinically important deterioration in COPD
title_sort long-term outcomes following first short-term clinically important deterioration in copd
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245880/
https://www.ncbi.nlm.nih.gov/pubmed/30453972
http://dx.doi.org/10.1186/s12931-018-0928-3
work_keys_str_mv AT nayaianp longtermoutcomesfollowingfirstshorttermclinicallyimportantdeteriorationincopd
AT tombslee longtermoutcomesfollowingfirstshorttermclinicallyimportantdeteriorationincopd
AT muellerovahana longtermoutcomesfollowingfirstshorttermclinicallyimportantdeteriorationincopd
AT comptonchristopher longtermoutcomesfollowingfirstshorttermclinicallyimportantdeteriorationincopd
AT jonespaulw longtermoutcomesfollowingfirstshorttermclinicallyimportantdeteriorationincopd